2017-2018年流感流行季河北省乙型Yamagata流感病毒耐药性及耐药位点分析  

Drug resistance and drug-resistant sites of influenza B/Yamagata virus in Hebei province during 2017-2018

作　　者：姜彩肖[1] 韩光跃[1] 李岩[1] 刘艳芳[1] 刘兰芬[1] 齐顺祥[1] Jiang Caixiao;Han Guangyue;Li Yan;Liu Yanfang;Liu Lanfen;Qi Shunxiang(Institute of Prevention and Treatment for Viral Diseases,Hebei Center for Disease Control and Prevention,Shijiazhuang 050021,China)

机构地区：[1]河北省疾病预防控制中心病毒病防治所,石家庄050021

出　　处：《国际病毒学杂志》2021年第4期292-295,共4页International Journal of Virology

基　　金：2019年度河北省医学科学研究课题计划(20190142)。

摘　　要：目的分析河北省2017-2018年流感监测年度乙型Yamagata流感病毒对神经氨酸酶抑制剂(neuraminidase inhibitor,NAI)的耐药情况,为流感的临床治疗及预防控制提供依据。方法选取28株乙型Yamagata流感病毒,检测病毒对奥司他韦和扎那米韦的药物敏感性。选取14株乙型Yamagata流感病毒,提取核酸后对神经氨酸酶(neuraminidase,NA)基因进行PCR扩增,测序后对耐药位点进行分析。结果选取的28株乙型Yamagata流感病毒全部对奥司他韦和扎那米韦敏感,对奥司他韦的半数抑制浓度(half maximal inhibitory concentration,IC_(50))平均为13.93 nM(4.54~32.07 nM),对扎那米韦的IC_(50)平均数为1.38 nM(0.14~5.61 nM)。NA基因的全部耐药位点未发现耐药突变。结论河北省2017-2018年流行的乙型Yamagata流感病毒对NAI类药物敏感。Objective To analyze the resistance to neuraminidase inhibitors(NAI)of influenza B/Yamagata lineage virus strains in Hebei province during 2017-2018,so as to provide basis for clinical treatment and prevention and control of influenza.Methods A total of 28 stains of confirmed influenza B/Yamagata lineage virus were selected to test the drug sensitivity of the virus to oseltamivir and zanamivi.Fourteen stains of the virus were selected for viral nucleic acid extraction and neuraminidase(NA)gene amplification.The drug-resistant mutation sites were analyzed after sequencing.Results All 28 strains of influenza B/Yamagata lineage virus were sensitive to oseltamivir and zanamivir.The median half maximal inhibitory concentration(IC50)for oseltamivir was13.93 nM(ranged 4.54-32.07 nM),and the IC50 to zanamivir was 1.38 nM(ranged 0.14-5.61 nM).No drug-resistant mutation site was observed.Conclusions Influenza B/Yamagata lineage virus stains prevalent in Hebei province during 2017-2018 were sensitive to NAI.

关 键 词：乙型Yamagata流感 神经氨酸酶抑制剂 耐药性 

分 类 号：R511.7[医药卫生—内科学]